KLK3 and cancer: Combining age, total PSA and hK2MoM values (other markers added little or no discrimination) yielded a 1.2%FPR (95% CI 0.2–4.8%) for a 90% DR (59–98%) in men who died of or with aprostate cancer diagnosis within 5 years of blood collection (risk cut-off 1in 20), two-thirds less than the 4.5% FPR using total PSA alone measured inng/ml for the same 90% DR (cut-off 3.1 ng/ml).